Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Intracoronary injection of glycoprotein IIb/IIIa, abciximab, as adjuvant therapy in primary coronary intervention.

Rognoni A, Lupi A, Cavallino C, Rosso R, Veia A, Bacchini S, Bongo AS.

Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):89-95. Review.

PMID:
23394547
2.

Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.

Desch S, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Pauschinger M, Kerber S, Kleinertz K, de Waha S, Eitel I, Schuler G, Thiele H.

J Am Coll Cardiol. 2013 Sep 24;62(13):1214-5. doi: 10.1016/j.jacc.2013.06.014. Epub 2013 Jul 10. No abstract available.

3.
4.

Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.

Xu Q, Yin J, Si LY.

Int J Cardiol. 2013 Jan 20;162(3):210-9. doi: 10.1016/j.ijcard.2012.06.001. Epub 2012 Jul 4.

PMID:
22769575
5.

Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.

Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, Fürnau G, Lurz P, Wetzel S, Schuler G, Thiele H.

Clin Res Cardiol. 2012 Feb;101(2):117-24. doi: 10.1007/s00392-011-0372-6. Epub 2011 Oct 21.

PMID:
22015616
8.

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.

Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15.

9.

Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.

Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G; Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators.

Am Heart J. 2010 Apr;159(4):547-54. doi: 10.1016/j.ahj.2009.12.038.

PMID:
20362711
11.

Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.

Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators.

Am Heart J. 2004 May;147(5):865-73.

PMID:
15131544
12.

Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Piccolo R, Eitel I, Galasso G, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F.

Vascul Pharmacol. 2015 Oct;73:32-7. doi: 10.1016/j.vph.2015.06.001. Epub 2015 Jun 10.

PMID:
26071862
13.

Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.

Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G.

Platelets. 2012;23(4):274-81. doi: 10.3109/09537104.2011.619602. Epub 2011 Oct 11.

PMID:
21988317
14.
15.

Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein IIb/IIIa antagonism.

Radke PW, Janssens U, Schwarz ER, vom Dahl J.

J Invasive Cardiol. 1999 Nov;11(11):679-81.

PMID:
10745462
16.

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.

Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.

Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

18.

Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.

De Vita M, Coluccia V, Burzotta F, Romagnoli E, Trani C.

Curr Vasc Pharmacol. 2012 Jul;10(4):448-53.

PMID:
22339256
19.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

Supplemental Content

Support Center